RE:Diagnostic testAdd it all up... This deal was six years ago... If CZO was to sell the diagnostic test for upfront cash upon approval for the pediatric market(the most important market) what could it get?
US$24 million upfront...
US$179 million in milestone payments linked to pediatric approval and revenue...
70% of pediatric trial costs covered...
15-18% royalties...
prophetoffactz wrote: It's six years after this deal. The pediatric trial costs have been absorbed as well as the time. Novo Nordisk bought them out and paid ~C$250 million(cash, equity) plus tiered royalties. Gilles should have a very good idea about the new deal. H.C. Waignwright has a C$100 million market cap target for AEZS.
- A wholly-owned subsidiary of Strongbridge Biopharma plc has snapped up the North American rights to Aeterna Zentaris Inc.‘s lead product, Macrilen.
- Aeterna Zentaris will get a much needed $24 million upfront, and royalties for the patent life of the drug, at a rate of 15% for sales up to $75 million and 18% above $75 million. After patent expiry, royalties will drop to 5%.
- Strongbridge will also pay milestone payments of up to $179 million on sales targets and on a pediatric U.S. approval, and will fund 70% of pediatric development costs.
- Post-review, Aeterna Zentaris strikes commercialization deal | BioPharma Dive